11
Views
22
CrossRef citations to date
0
Altmetric
Original Article

The Use of a Long-Acting Somatostatin Analogue in the Treatment of Advanced Endocrine Malignancies with Gastrointestinal Symptoms

&
Pages 938-942 | Received 08 Jan 1987, Accepted 20 Mar 1987, Published online: 08 Jul 2009
 

Abstract

Four patients with advanced endocrine malignancies were treated with a somatostatin analogue (SMS 201-995) for palliation of hormone-induced symptoms during F6 months. Two had the carcinoid syndrome (one midgut and one foregut). one had medullary thyroid carcinoma and an ectopic ACTH syndrome, and one patient had a metastatic gastrinoma. The carcinoid patients had excellent symptomatic relief with a low dose of the drug. So μg subcutaneously twice daily, in one case despite progression of tumour disease and biochemical tumour markers. These findings indicate an action of the drug not only on hormonal release hut also at peripheral sites. The patient with medullary thyroid carcinoma had relief of gastrointestinal symptoms when the drug dose was increased (100μg twice daily). The levels of ACTH in peripheral blood were reduced. hut not the calcitonin levels. The gastrinoma patient had undergone a major pancreatic resection (Whipple procedure) and was treated with omeprazole. SMS 201-995 reduced the peripheral gastrin levels acutely. hut during the treatment fasting gastrin values increased. and the turnour growth progressed. Treatment was stopped owing to elevated fasting glucose level, increased steatorrhoea. and clinical attacks of cholangitis. Special attention is advocated for patients with major pancreatic resection and hiliary reconstruction, who may he susceptible to physiological effects of somatostatin (or its analoguest—that is, impaired insulin release and decreased motility

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.